Final, Group 3, Phase II Trials, page-3

MJP Similarly have been buying regularly for 7 plus years and have never sold and dont intend to. Re the value at the end of the year the Immupel technology must surely be worth more than 2 cents on its own even if Parkinson application was not succesful. So I see far less down side risk.... but the potential upside ......pick your number.!!

Hope to hear that phase 3 6 patients given go ahead imminently by Medical board and agree NZ Trader it would be timely to get an update on the original 4 trial patients and of course to hear from Carol again would be terrific . However I also would understand why she may not want herself in public domain again.

Pretty exciting this next set of 6 patients with 4 of them receiving a triple dose and to both sides of the rain. Appreciate more may not always be better but the results will be intriuging.!